
NDRA Stock Forecast & Price Target
NDRA Analyst Ratings
Bulls say
ENDRA Life Sciences Inc. is poised to benefit significantly from anticipated FDA approval within the next year, which could drive stock performance substantially according to a Net Present Value (NPV) analysis indicating considerable upside potential. The TAEUS technology is expected to provide a more accurate and cost-effective means of diagnosing and monitoring Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), addressing an urgent need in the healthcare market where current diagnostic tools are inadequate. Moreover, the application of TAEUS beyond liver conditions into areas such as energy-based surgical procedures further underscores the platform's versatility and potential for broad clinical impact.
Bears say
ENDRA Life Sciences Inc reported a net loss of $1.6 million, translating to an earnings per share (EPS) of $(2.10), which fell short of internal estimates of $(1.95). The company is also experiencing significant balance sheet and liquidity risks, compounded by the challenges of demonstrating the safety and efficacy of its product in clinical trials, as well as obtaining the necessary regulatory approvals for commercialization. Additional factors contributing to a negative outlook include potential difficulties in securing appropriate reimbursement, intense competition, and changes in investor sentiment within the biotech and medtech sectors.
This aggregate rating is based on analysts' research of ENDRA Life Sciences and is not a guaranteed prediction by Public.com or investment advice.
NDRA Analyst Forecast & Price Prediction
Start investing in NDRA
Order type
Buy in
Order amount
Est. shares
0 shares